LRIG1 knockdown CD19 chimeric antigen receptor T cells

LRIG1 knockdown CD19 chimeric antigen receptor T cells are an experimental cell therapy designed to treat B-cell malignancies. This therapy involves genetically engineering T cells to express a chimeric antigen receptor (CAR) targeting the CD19 antigen, while simultaneously knocking down the expression of Leucine Rich Repeats and Immunoglobulin Like Domains 1 (LRIG1). LRIG1 has been identified as an inhibitory receptor that interacts with V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) to limit T cell persistence and function. By reducing LRIG1 expression, these CAR-T cells are intended to overcome VISTA-mediated immunosuppression, leading to enhanced durability, improved persistence, and superior anti-tumor efficacy compared to standard CD19 CAR-T therapies. Preclinical studies in murine models of B-cell lymphoma and melanoma have demonstrated that LRIG1 ablation improves CAR-T cell persistence and leads to long-term tumor regression.

Other names

LRIG1 deficient CD19scFV human CAR T cellsLRIG-1 deficient CD19scFV human CAR T cellsLRIG 1 deficient CD19scFV human CAR T cellsLRIG1-ablated CD19 CAR T cellsLRIG-1-ablated CD19 CAR T cellsLRIG 1-ablated CD19 CAR T cells